prikaz prve stranice dokumenta Targeting PVR (CD155) and its receptors in anti-tumor therapy
  Download
PDF 1.43 MB
Scientific paper - Review paper
Targeting PVR (CD155) and its receptors in anti-tumor therapy
Cellular and Molecular Immunology, 16 (2018), 1; 40-52. https://doi.org/10.1038/s41423-018-0168-y
Kučan Brlić, Paola; Lenac Roviš, Tihana; Cinamon, Guy; Tsukerman, Pini; Mandelboim, Ofer; Jonjić, Stipan

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Kučan Brlić, P., Lenac Roviš, T., Cinamon, G., Tsukerman, P., Mandelboim, O. & Jonjić, S. (2018). Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology, 16. (1), 40-52. doi: 10.1038/s41423-018-0168-y

Kučan Brlić, Paola, et al. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology, vol. 16, no. 1, 2018, pp. 40-52. https://doi.org/10.1038/s41423-018-0168-y

Kučan Brlić, Paola, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim and Stipan Jonjić. "Targeting PVR (CD155) and its receptors in anti-tumor therapy." Cellular and Molecular Immunology 16, no. 1 (2018): 40-52. https://doi.org/10.1038/s41423-018-0168-y

Kučan Brlić, P., et al. (2018) 'Targeting PVR (CD155) and its receptors in anti-tumor therapy', Cellular and Molecular Immunology, 16(1), pp. 40-52. doi: 10.1038/s41423-018-0168-y

Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular and Molecular Immunology [Internet]. 2018 October 01 [cited 2024 November 29];16(1):40-52. doi: 10.1038/s41423-018-0168-y

P. Kučan Brlić, T. Lenac Roviš, G. Cinamon, P. Tsukerman, O. Mandelboim and S. Jonjić, "Targeting PVR (CD155) and its receptors in anti-tumor therapy", Cellular and Molecular Immunology, vol. 16, no. 1, pp. 40-52, October 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:504690. [Accessed: 29 November 2024]

Metadata
Title (english)Targeting PVR (CD155) and its receptors in anti-tumor therapy
AuthorPaola Kučan Brlić
AuthorTihana Lenac Roviš
AuthorGuy Cinamon
AuthorPini Tsukerman
AuthorOfer Mandelboim
AuthorStipan Jonjić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Center for Proteomics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Abstract (english)
Poliovirus receptor (PVR, CD155) has recently been gaining scientific interest as a therapeutic target in the field of tumor immunology due to its prominent endogenous and immune functions. In contrast to healthy tissues, PVR is expressed at high levels in several human malignancies and seems to have protumorigenic and therapeutically attractive properties that are currently being investigated in the field of recombinant oncolytic virotherapy. More intriguingly, PVR participates in a considerable number of immunoregulatory functions through its interactions with activating and inhibitory immune cell receptors. These functions are often modified in the tumor microenvironment, contributing to tumor immunosuppression. Indeed, increasing evidence supports the rationale for developing strategies targeting these interactions, either in terms of checkpoint therapy (i.e., targeting inhibitory receptors) or in adoptive cell therapy, which targets PVR as a tumor marker.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleCellular and Molecular Immunology
Numberingvol. 16, no. 1, pp. 40-52
p-ISSN1672-7681
e-ISSN2042-0226
DOIhttps://doi.org/10.1038/s41423-018-0168-y
URN:NBNurn:nbn:hr:184:504690
Online first2018-10-01
Document URLhttp://www.nature.com/articles/s41423-018-0168-y
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) icon
Created on2018-10-11 08:36:12